STOCK TITAN
  1. Home
  2. News
  3. XTNT

Xtant Medical Holdings, Inc. - $XTNT STOCK NEWS

Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: $XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xtant Medical Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xtant Medical Holdings's position in the market.

News
Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024
Rhea-AI Summary

Xtant Medical Holdings, Inc. (NYSE American:XTNT) will release its first quarter 2024 financial results on May 15, 2024. The global medical technology company specializing in spinal disorder surgical solutions will have a conference call hosted by President Sean Browne and CFO Scott Neils at 4:30 PM ET on the same day. Details can be accessed through the provided conference dial-in or webcast link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
Rhea-AI Summary

Xtant Medical Holdings, Inc. announced the full commercial launch of two amniotic membrane allografts, SimpliGraft™ and SimpliMax™, for chronic and acute wounds. The products are dehydrated, terminally irradiated, single and dual-layer amniotic membrane sheets intended to provide protective coverage from the surrounding environment when applied topically. Manufactured at Xtant’s biologics processing center in Belgrade, Montana, the company aims to position itself as a leader and innovator in advanced biologic therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
-
News
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
Rhea-AI Summary
Xtant Medical Holdings, Inc. reports record annual revenue of $91.3 million in 2023, a 58% increase year-over-year. The company establishes full-year 2024 revenue guidance of $112 million to $116 million, reflecting a 23% to 27% growth compared to 2023. Xtant Medical achieved positive adjusted EBITDA for three consecutive quarters in 2023, with a gross margin increase of 540 basis points. The company attributes revenue growth to independent agent and private label sales, acquisitions of Coflex, CoFix, and Surgalign product lines. Operating expenses increased due to additional sales commissions, higher employee compensation, legal expenses, and amortization of intangible assets. Non-GAAP adjusted EBITDA for 2023 was $1.0 million, compared to a loss of $3.0 million in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.97%
Tags
none
News
Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024
Rhea-AI Summary
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its financial results for Q4 and full year 2023 on April 1, 2024. The conference call hosted by the President and CFO will discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
earnings
-
News
Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial
Rhea-AI Summary
Xtant Medical Holdings, Inc. amends credit agreement with MidCap Financial Trust, increasing commitment to $17.0 million and term loan by $10.0 million. Maturity dates extended to 2029, revenue requirements reset, EBITDA requirements removed, and interest rate margin reduced to 6.50%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
-
News
Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference
Rhea-AI Summary
Xtant Medical Holdings, Inc. (XTNT) CEO to present at TD Cowen 44th Annual Healthcare Conference. The presentation will be on March 4, 2024, at 12:50 p.m. ET in Boston. A live webcast will be accessible on the Company’s website. A replay will be available for 90 days post-presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.31%
Tags
conferences
News
Xtant Medical to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Xtant Medical Holdings, Inc. (XTNT) will participate in two upcoming investor conferences: Canaccord Genuity 2024 Musculoskeletal Conference and BTIG Medtech, Digital Health, Life Science and Diagnostic Tools Conference. President and CEO, Sean Browne, and CFO, Scott Neils, will present and participate in 1x1 meetings with institutional investors. The live webcast of the Canaccord presentation will be available on the Company's website, with a replay following the conclusion of the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
-
News
Xtant Medical to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announces participation in Jefferies London Healthcare Conference and 14th Annual Craig-Hallum Alpha Select Conference. President and CEO, Sean Browne, to present at Jefferies conference. Live webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
News
Xtant Medical Announces Record Third Quarter Revenue of $25 Million
Rhea-AI Summary
Xtant Medical Holdings, Inc. (XTNT) raises 2023 Annual Revenue Guidance to $88 Million - $91 Million, reports record third quarter revenue of $25 million, an 18% organic growth, and a 73% year-over-year increase. Gross margin for Q3 2023 was 61.3% and net income totaled $9.2 million. The company also plans to host a conference call to discuss the financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
News
Xtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023
Rhea-AI Summary
Xtant Medical Holdings, Inc. will release its financial results for Q3 2023 on November 9, 2023. The company is a global medical technology company focused on surgical solutions for spinal disorders. President and CEO Sean Browne, and CFO Scott Neils, will host a conference call at 9:00 AM ET on the same day to review the results. The conference call details are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
earnings
Stock XTNT logo
Xtant Medical Holdings, Inc.

NYSE:XTNT

XTNT Rankings

#4248 Ranked by Market Cap
#224 Ranked by Stock Gains
N/A Ranked by Dividends

XTNT Stock Data

106.31M
39.72M
8.16%
69.27%
0.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BELGRADE

About XTNT

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.